Form 4: Hims & Hers CEO Andrew Dudum Executes Pre-Planned Stock Sales and Option Exercises

Hims & Hers Health, Inc. CEO Andrew Dudum reported significant stock transactions, including the exercise of stock options and sales of Class A Common Stock, primarily conducted under a Rule 10b5-1 trading plan.

Summary

• Andrew Dudum, Chief Executive Officer, Director, and 10% Owner of Hims & Hers Health, Inc. (HIMS), reported multiple transactions involving the company's Class A Common Stock.
• On June 13, 2025, Mr. Dudum acquired 164,368 shares of Class A Common Stock through the exercise/conversion of derivative securities (RSUs) and disposed of 90,672 shares at $55.48 for tax liability.
• On June 16, 2025, he exercised stock options to acquire a total of 125,335 shares (108,334 shares and 17,001 shares) at an exercise price of $2.43 per share.
• Between June 16 and June 17, 2025, Mr. Dudum sold a total of 240,771 shares of Class A Common Stock through multiple transactions at weighted average prices ranging from $56.3526 to $59.4469.
• All stock option exercises and sales reported were executed pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024.
• Following these transactions, Mr. Dudum's direct beneficial ownership of Class A Common Stock is 95,105 shares, and his indirect beneficial ownership through various trusts totals 8,728,506 shares.
• The document also details the vesting schedules for various Restricted Stock Units (RSUs) and the conversion terms of stock options related to the company's 2021 business combination transaction.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there are significant sales by the CEO, these are largely offset by the fact that they were pre-planned under a Rule 10b5-1 trading plan, which reduces the negative signal typically associated with insider selling. The exercises of options at a low price also indicate the realization of value from long-term incentives.

Positives

• The acquisition of 164,368 shares through RSU conversions on June 13, 2025, indicates vesting of equity compensation.
• The exercise of 125,335 stock options at a low exercise price of $2.43 per share on June 16, 2025, demonstrates the realization of value from long-term incentives.
• The existence of a Rule 10b5-1 trading plan, adopted on August 28, 2024, indicates that the sales were pre-scheduled and not based on immediate, non-public information, which can mitigate negative perceptions of insider selling.

Negatives

• The disposition of 90,672 shares for tax liability on June 13, 2025, represents a reduction in direct holdings.
• The sale of 240,771 shares of Class A Common Stock by the CEO between June 16 and June 17, 2025, represents a significant reduction in direct beneficial ownership, even if pre-planned.

Risks

• While the sales were pre-planned under a Rule 10b5-1 plan, significant insider selling, even if scheduled, can sometimes be perceived negatively by investors and may put downward pressure on the stock price.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details insider transactions and does not provide broader industry context or trends. It reflects individual equity management by a key executive within the direct-to-consumer healthcare industry.

Related Party Transactions

• Indirect beneficial ownership is held by the Trustee of Dudum Family Community Property Trust, AD 2022 GRAT 3, AD 2021 GRAT, AD 2022 GRAT, AD 2023 GRAT, AD 2022 GRAT 2, Dudum Family Heritage Trust UAD 8-10-2021, and AD 2025 GRAT 3.
• An in-kind transfer of 186,723 Class A Common Shares occurred from the Andrew Dudum 2015 Trust dated July 2, 2015, to the AD 2025 GRAT 3 dated May 27, 2025.

Stakeholder Impact

• Shareholders: The pre-planned nature of the sales under a 10b5-1 plan provides transparency and reduces concerns about opportunistic insider selling, but the volume of sales may still be noted by investors.
• Employees: The vesting of RSUs and exercise of stock options are standard equity compensation events, which can be positive for employee morale and retention.

Next Steps

• Ongoing service-based vesting of Restricted Stock Units (RSUs) in substantially equal quarterly installments on Company Quarterly Vesting Dates (March 15, June 15, September 15, and December 15).

Key Dates

Recommendation

Keywords

Hims & Hers Health, HIMS, SEC Form 4, Insider Trading, Stock Sales, Stock Options, RSU, Andrew Dudum, CEO, 10b5-1 plan, Equity Compensation